8 April 2014Americas

Teva asks US Supreme Court to stay ruling in Copaxone case

Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone (glatiramer acetate).

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

More on this story

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

More on this story

US Supreme Court split on Teva case

16 October 2014 The US Supreme Court was split yesterday (October 15) after hearing arguments in a high-profile case that will determine whether generic drug companies are free to market a cheaper version of Teva’s blockbuster multiple sclerosis drug.

Generics file Teva response in Copaxone battle

15 April 2014 A group of generic drug manufacturers has asked the US Supreme Court to allow a ruling that grants them permission to market a version of Teva’s multiple sclerosis drug Copaxone (glatiramer acetate).

More features

LSPN: In-house ‘chess game’ is the same, but the rules have changed

Life sciences leaders recognised at LSPN Awards USA 2025

UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body

LSPN: Counsel grapple with AI’s impact on training and critical thinking

'Nothing can stand in the way of our work': Ukraine resumes IP system

LSPN: Trump's policy storm causing chaos and confusion

Taylor Wessing expands in Europe with Paris team

LSPN: Using ‘the patentee’s friend’ in Section 112 claims